Key result
Vaccine candidates, including inactivated complete virus, recombinant VP1 protein, artificial peptides, VLPs, and live attenuated vaccines, are essential for combating EV71 outbreaks promptly.
Why the study?
Little is known regarding the pathogenesis of EV71, and host immune and molecular responses against the virus are not clearly determined.
This review highlights the pathogenesis of EV71 and the current landscape of antiviral drugs and vaccine candidates for managing infections and outbreaks.
Answers are grounded in this paper and cite their sources.
Supports urgent EV71 vaccine prioritization amid outbreaks; leaves open which candidates will demonstrate efficacy in trials.
Enterovirus 71 (EV71) is an infectious virus affecting all age groups of people around the world. It is one of the major aetiologic agents for HFMD (hand, foot and mouth disease) identified globally. It has led to many outbreaks and epidemics in Asian countries. Infection caused by this virus that can lead to serious psychological problems, heart diseases and respiratory issues in children younger than 10 years of age. Many studies are being carried out on the pathogenesis of the virus, but little is known. The host immune response and other molecular responses against the virus are also not clearly determined. This review deals with the interaction between the host and the EV71 virus. We discuss how the virus makes use of its proteins to affect the host's immunity and how the viral proteins help their replication. Additionally, we describe other useful resources that enable the virus to evade the host's immune responses. The knowledge of the viral structure and its interactions with host cells has led to the discovery of various drug targets for the treatment of the virus. Additionally, this review focusses on the antiviral drugs and vaccines developed by targeting various viral surface molecules during their infectious period. Furthermore, it is asserted that the improvement of prevailing vaccines will be the simplest method to manage EV71 infection swiftly. Therefore, we summarise numerous vaccines candidate for the EV71, such as the use of an inactivated complete virus, recombinant VP1 protein, artificial peptides, VLPs (viral-like particles) and live attenuated vaccines for combating the viral outbreaks promptly.
No takes yet. Share an insight, caveat, or question.
Swain et al. (2022) conducted a review in Enterovirus 71 (EV71) infection. EV71 vaccines and antiviral drugs was evaluated. Vaccine candidates, including inactivated complete virus, recombinant VP1 protein, artificial peptides, VLPs, and live attenuated vaccines, are essential for combating EV71 outbreaks promptly.
Synapse has enriched 10 related papers. Consider them for comparative context: